A combination of design issues and procedural lapses led one firm to release drug substance batches for its mRNA COVID-19 vaccine despite concerning levels of microbiological contamination and the use of expired materials.
Another firm struggled with particulate contamination of the cryopreservation bags for its autologous
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?